Full Press Release Details
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT.
SLDB
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Key Takeaway: Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT